Shares of Madrigal Pharmaceuticals (MDGL) jumped after Bloomberg reported, citing people familiar with the matter, that the company is working with Centerview Partners on a potential sale after receiving takeover interest. The talks are at an early stage and Madrigal, which just reported Phase 2 data in non-alcoholic steatohepatitis, may opt to continue operating independently, Bloomberg added. Madrigal shares are up 7%, or $20.29, to $303.00 in late morning trading. The company has nine employees and a market capitalization of around $4.5B. Shares of Intercept Pharmaceuticals (ICPT), which has a competing, and further along than Madrigal’s, drug to treat non-alcoholic steatohepatitis, are up 2% to $82.08.